Rhumbline Advisers Zynerba Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$0.3 - $0.43 $241 - $346	805 New	805 $0
Q2 2020 Aug 13, 2020	SELL	$3.31 - $6.54 $71,181 - $140,642	-21,505 Closed	0 $0
Q4 2019 Feb 05, 2020	BUY	$5.61 - $8.57 $3,500 - $5,347	624 Added 2.99%	21,505 $130,000
Q3 2019 Oct 23, 2019	BUY	$7.56 - $15.44 $6,660 - $13,602	881 Added 4.41%	20,881 $158,000
Q2 2019 Aug 14, 2019	BUY	$5.4 - $15.5 $108,000 - $310,000	20,000 New	20,000 $271,000
Q2 2018 Aug 06, 2018	SELL	$7.98 - $12.39 $84,404 - $131,049	-10,577 Closed	0 $0
Q1 2018 May 02, 2018	BUY	$8.49 - $13.46 $2,037 - $3,230	240 Added 2.32%	10,577 $92,000
Q4 2017 Feb 09, 2018	SELL	$8.69 - $14.59 $63,019 - $105,806	-7,252 Reduced 41.23%	10,337 $129,000
Q3 2017 Nov 06, 2017	BUY	$5.73 - $9.44 $100,784 - $166,040	17,589	17,589 $147,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.